News

A family of six mitochondrial small humanin-like peptides (SHLPs) showed promising effects on cell survival and metabolism in preclinical studies of aging, a finding with long-reaching implications for age-related conditions such as Alzheimer’s disease. The findings were announced by the biotechnology company CohBar, which holds the exclusive license for developing SHLPs…

  New guidelines for Alzheimer’s disease patient care and caregiver support developed by the Alzheimer’s Association’s National Plan Care and Support Milestone Workgroup are detailed in a paper, “Report on milestones for care and support under the U.S. National Plan to Address Alzheimer’s Disease,” published…

A review analysis by Professor Melissa Schilling, a strategy and innovation expert at the New York University’s Stern School of Business, suggests a strong link between diabetes and Alzheimer’s disease. The study, “Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease,” was published in…

Face recognition difficulties in Alzheimer’s patients have typically been attributed to underlying episodic and semantic memory impairment. Dr. Sven Joubert, Ph.D., from the Centre de recherche de l’Institut universitaire de gériatrie de Montréal, and colleagues have found that more than causing memory problems, Alzheimer’s also impairs visual face perception, a…

Researchers at Université Laval in Canada demonstrated that aging mice in a model of Alzheimer’s disease (AD) were less able to regulate their body temperatures, and when exposed to a cold environment showed increased AD manifestations. These results suggest correction of thermoregulation might be a therapeutic avenue for Alzheimer’s. The study, “Impaired thermoregulation and…

Dublin, Ireland-based global pharmaceutical company Allergan and Heptares Therapeutics, a clinical-stage pharmaceutical company whose proprietary technologies have created new medicines with the potential to transform Alzheimer’s disease, have entered into a global research and development and commercialization partnership for the treatment of Alzheimer’s…

Oryzon Genomics recently announced the dosing of a first subject in its Phase 1 trial of oral LSD1-MAOB dual selective inhibitor ORY-2001, targeting memory loss and cognitive decline in Alzheimer’s disease. The single and multiple ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of ORY-2001 in healthy subjects. The trial is randomized, double-blind,…

Two important Alzheimer’s research organizations, Researchers Against Alzheimer’s (RA2) and Us Against Alzheimer’s (UsA2), will host an Alzheimer’s Talks Teleconference on April 11 to discuss recently released findings of an analysis of late-stage drug candidates to treat the disease. Significant findings in the analysis, released in March, include: There are 17 drugs in late-stage…

Researchers have identified a group of agricultural chemicals — pesticides and fungicides — that constitute environmental risk factors for neurological and neurodegenerative diseases. A recent study found that a number of these chemicals produce gene expression changes in mouse neurons similar to those observed in people with autism, Alzheimer’s disease, and other conditions. The paper, “…

Before any signs of cognitive decline start showing, neuronal synaptic connections are lost in mice destined to develop Alzheimer’s. New research shows that microglia – brain immune cells – destroy synapses in a fashion resembling processes in the developing brain, suggesting that it might be possible to develop drugs targeting…